Daily Management Review

Pfizer & Merck’s Joint Venture In Diabetes Drug Gets EMA Committee’s Recommendation


Steglatro will be treating type II diabetes orally.

One panel of European Medicines Agency, shortly called EMA, has come up with a recommendation of “granting marketing approval” towards a drug for diabetes that has been jointly developed by Merck & Co and Pfizer Inc.
The said recommendation of the EMA panel for “Medicinal Products for Human Use” can be a booster to the European Commission bound companies. The drug, an oral treatment used for treating “Type II diabetes”, will be coming to the market under the name of Steglatro.
Steglatro is a “SGLT2 inhibitors” which will help the patients’ “excess glucose” to be expelled “through urine”. While Reuters added:
“In December, Merck and Pfizer won approval from the U.S. Food and Drug Administration for Steglatro as a single therapy and in fixed-dose combinations with Merck’s diabetes drug Januvia or with metformin, an older generic treatment typically given to newly diagnosed patients”.
Diabetes can cause severe organ damage affecting the “eyes and kidneys” besides it can also raise significant risk of “heart attack and stroke”. With the progression of “type II diabetes” many patients require “additional treatments” to keep their “blood sugar levels” under “better control”.

Science & Technology

Credit Suisse: China will become the leader in AI sphere

Five new technologies that will change the world

Over 500 Genes Impacting Intelligence Identified By Scientists

MIT Scientists Say It Could Be Just 13 Years For Commercialization Of Nuclear Fusion

Apple patents MacBook with a keyboard screen

Vero: An Instagram killer?

Wacky Weather Causes ‘Split In The Polar Vortex’

Smart And Adaptive Artificial Eye Developed By Researchers At Harvard

NASA’s Mars Mission To Make Use Of Cold War-Era Atomic Rockets

Israel Completes Mars Habitat Simulation Experiment

World Politics

World & Politics

Ten world's largest importers of weapons

Christine Lagarde: there’s no winner in trade wars

10 best countries for freelancers

Alarming Concerns Or Driving Force Towards Green Energy? – Bitcoin Growth Comes At Environmental Cost

Catalan authorities refuse to greet the King of Spain

Ten Top Politicians To Be Investigated By Greek Parliament On Charges Of Taking Bribes From Novartis

The cloudy future of Saudi Arabia

Australia To Welcome Britain On The Latter’s Interest In Joining TPP